Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma
Authors:
Open Access
- 1 February 2021
- Vol. 6 (1) , 100020
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancerCritical Reviews in Oncology/Hematology, 2013
- Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinomaOral Oncology, 2012
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving SorafenibThe Oncologist, 2011
- Current Strategy for Staging and Treatment: The BCLC Update and Future ProspectsSeminars in Liver Disease, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Inflammation and cancerNature, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999